NantHealth Inc (NH) COO Ronald Allen Louks Sells 26,820 Shares
NantHealth Inc (NYSE:NH) COO Ronald Allen Louks sold 26,820 shares of NantHealth stock in a transaction dated Friday, October 6th. The stock was sold at an average price of $4.28, for a total transaction of $114,789.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of NantHealth Inc (NYSE:NH) traded down 4.06% during trading on Tuesday, reaching $4.02. 243,063 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $4.44 and its 200 day moving average price is $4.44. The firm’s market capitalization is $490.22 million. NantHealth Inc has a 52 week low of $3.96 and a 52 week high of $13.80.
NantHealth (NYSE:NH) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.32). NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The firm had revenue of $26.23 million for the quarter, compared to analysts’ expectations of $31.28 million. During the same period in the prior year, the company posted ($0.15) earnings per share. NantHealth’s quarterly revenue was down 16.7% compared to the same quarter last year. Analysts predict that NantHealth Inc will post ($0.70) EPS for the current fiscal year.
A number of equities analysts have issued reports on the stock. Jefferies Group LLC restated a “buy” rating and set a $5.00 target price on shares of NantHealth in a research report on Thursday, September 28th. BidaskClub upgraded shares of NantHealth from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. Finally, Canaccord Genuity restated a “buy” rating and set a $6.00 target price (down previously from $8.00) on shares of NantHealth in a research report on Monday, August 21st. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $9.25.
Hedge funds have recently bought and sold shares of the business. TIAA CREF Investment Management LLC lifted its stake in NantHealth by 68.6% during the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock valued at $100,000 after buying an additional 8,217 shares in the last quarter. Alliancebernstein L.P. purchased a new stake in shares of NantHealth in the second quarter worth approximately $102,000. Bank of America Corp DE lifted its position in shares of NantHealth by 366.4% in the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock worth $125,000 after purchasing an additional 19,694 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of NantHealth in the second quarter worth approximately $121,000. Finally, Teachers Advisors LLC lifted its position in shares of NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after purchasing an additional 24,588 shares in the last quarter.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.